RT Journal Article
SR Electronic
T1 Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 369
OP 373
DO 10.1124/jpet.102.033340
VO 302
IS 1
A1 Marier, Jean-Francois
A1 Vachon, Pascal
A1 Gritsas, Ari
A1 Zhang, Jie
A1 Moreau, Jean-Pierre
A1 Ducharme, Murray P.
YR 2002
UL http://jpet.aspetjournals.org/content/302/1/369.abstract
AB Pharmacokinetics of trans-resveratrol in its aglycone (RESAGL) and glucuronide (RESGLU) forms were studied following intravenous (15 mg/kg i.v.) and oral (50 mg/kg p.o.) administration of trans-resveratrol in a solution of β-cyclodextrin to intact rats. In addition, the enterohepatic recirculation of RESAGL and RESGLU was assessed in a linked-rat model. Multiple plasma and urine samples were collected and concentrations of RESAGL and RESGLU were determined using an electrospray ionization-liquid chromatography/tandem mass spectrometry method. After i.v. administration, plasma concentrations of RESAGL declined with a rapid elimination half-life (T1/2, 0.13 h), followed by sudden increases in plasma concentrations 4 to 8 h after drug administration. These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RESAGL(T1/2TER, 1.31 h). RESAGLand RESGLU also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, withT1/2TER of 1.48 and 1.58 h, respectively. RESAGL bioavailability was 38% and its exposure was approximately 46-fold lower than that of RESGLU (AUCinf, 7.1 versus 324.7 μmol·h/l). Enterohepatic recirculation was confirmed in the linked-rat model since significant plasma concentrations of RESAGL and RESGLU were observed in bile-recipient rats at 4 to 8 h. The percentages of the exposures of RESAGL and RESGLU that were due to enterohepatic recirculation were 24.7 and 24.0%, respectively. The fraction of drug excreted in the urine over a period of 12 h was negligible. These results confirm that RESAGL is bioavailable and undergoes extensive first-pass glucuronidation, and that enterohepatic recirculation contributes significantly to the exposure of RESAGL and RESGLU in rats. The American Society for Pharmacology and Experimental Therapeutics